Do BTK Inhibitors Lead to Secondary Cancers?
Patients with CLL prescribed BTK inhibitors may have a higher chance of developing secondary cancers, according to recent research.
Patients with chronic lymphocytic leukemia who take BTK inhibitors tend to have a higher rate of secondary cancers than the general population, explained David A. Bond, MD, an assistant professor at The Ohio State University.
In a study including 691 patients, Bond and his team catalogued secondary cancer instances, and found that these diagnoses were the second leading cause of death in the population.